The Dutch biopharmaceutical company OctoPlus N.V. today celebrates a successful introduction by listing 16.2 million shares on Euronext Amsterdam.
The IPO included the offering of 4.3 mln new shares, raising EUR 20 mln. The opening price was € 4.64. Based on this opening price, the company has a market capitalisation of € 75 mln. Octoplus is the second biotech listing in Amsterdam this year and brings the number of new listings on Euronext Amsterdam so far this year to 8.
OctoPlus N.V. is a product-oriented biopharmaceutical company committed to the development of improved pharmaceutical products.
“We are very happy to receive OctoPlus N.V. on Euronext Amsterdam. It is part of a growing segment of biotech companies that use our exchange to attract fresh capital to invest in the development of their products’, says Joost van der Does de Willebois, Euronext CFO and member of the Managing Board.
